Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. - Wikidata - wikimedia - TriplyDB

Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.

Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.

http://www.wikidata.org/entity/Q34369188

about

What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Rituximab for Rheumatoid Arthritis.[Medication treatment of rheumatoid arthritis with a history of malignancy. Epidemiological data].A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort.Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor.How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.Oral Cancer and Oral Precancerous Lesions in Inflammatory Bowel Diseases: A Systematic Review.The impact of cancer development on the risk of mycobacterial diseases among rheumatoid arthritis patients.Safety profile of biological therapies for treating rheumatoid arthritis.Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions.Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis.Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis.Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study.Collaborative Power of Nrf2 and PPARγ Activators against Metabolic and Drug-Induced Oxidative Injury Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions

P2860

Q28074148-20BF36E5-72F9-4AF7-B803-228833847E31 Q28080246-A4094F1A-0B52-4106-BD4A-688CBD68B9FA Q31036951-B0023E7C-3EFA-4603-BD56-119F60604A71 Q33760824-C3BD25F9-786F-438F-9C97-8FD9A12F5913 Q34520662-6FD98CA3-9E7F-4B63-AAAF-28E6AD6D729D Q35813092-96BD8997-4494-4BEC-A34D-2B81C02C6C28 Q37656273-1F674C20-A4EF-4010-B464-63B0B53D6B26 Q38411038-86883ECF-95FA-477E-A990-66C821721FE9 Q38545129-E7AB5030-98E4-4DB2-9B85-9179ADD623A9 Q38665320-92795A2F-B65E-4096-B0DC-79D0ED431594 Q38665700-AF6E7D46-6506-46BB-A3CB-8886303888E0 Q38954348-4C3A7276-071E-4C90-9464-33348EB01B77 Q39248920-3DEC908A-27C6-4DCB-A172-9C99CA3A11E4 Q39309064-898CD917-051D-4E26-9CE4-3349FA57A664 Q39603215-5EF5B107-D048-43B6-BF1C-12130420186F Q40039414-D67D604F-C9E6-433A-8861-FD636231BEAE Q40298171-89F9A0E9-E70B-4328-A57F-FC5B3DC76178 Q41449206-744E29C4-698A-4D10-86AA-5EFA93990904 Q41650730-9F14E654-F987-405D-9322-355D8D39ED07 Q47229003-FDF7C12A-9385-45D2-9F0A-CB38FF48DE13 Q47620758-55ED68F2-C17E-4F1F-ACD5-D7C240B5FADD Q48825054-4A6E3B47-D046-4C84-9716-BC2C9B9256DC Q56835543-B81CF7BF-490B-44A4-8D2E-8528E81BB032

P2860

Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.

http://www.wikidata.org/entity/Q34369188

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Comparative cancer risk associ ...... odifying anti-rheumatic drugs.

@ast

Comparative cancer risk associ ...... odifying anti-rheumatic drugs.

@en

Comparative cancer risk associ ...... odifying anti-rheumatic drugs.

@nl

type

label

Comparative cancer risk associ ...... odifying anti-rheumatic drugs.

@ast

Comparative cancer risk associ ...... odifying anti-rheumatic drugs.

@en

Comparative cancer risk associ ...... odifying anti-rheumatic drugs.

@nl

prefLabel

Comparative cancer risk associ ...... odifying anti-rheumatic drugs.

@ast

Comparative cancer risk associ ...... odifying anti-rheumatic drugs.

@en

Comparative cancer risk associ ...... odifying anti-rheumatic drugs.

@nl

P1433

Q34369188-FC7A8DCE-E78C-43EF-9B9B-440C78B44192

P1476

Q34369188-5FBCE756-C790-436B-8319-495024A6F48F

P2093

Q34369188-02A7B5BE-BE5C-47F7-83D2-7AF06EFD9E7A

Q34369188-19483417-FC55-4A8A-A84A-1CD163DC485B

Q34369188-2E632858-2CF9-43FC-92FA-B9D1E87E6248

Q34369188-31F3FC14-E7D1-40BB-862E-1C3CBBF367A8

Q34369188-3BA23D5D-D799-4DC8-9503-0DBA9C15F004

Q34369188-4A1E17F4-4AB6-486A-A39B-939B605BF804

Q34369188-77A2FEE9-A2EE-4DB0-AEBF-449F9DF9A1BA

Q34369188-8723CC57-800D-4536-92DA-7E1522CE3A87

Q34369188-991B10AC-54BD-44D1-92FA-37ECF7EBBE31

Q34369188-FAE361AC-1494-4CF6-80E0-2DE91B1708CB

P304

Q34369188-473DF6D2-5037-49B6-BB1F-6BE71A6FD3DC

P31

Q34369188-31EF72DD-F5C4-443B-8805-37650D13275C

P356

Q34369188-FC85FC0F-4570-4979-AEEC-28E8137942B8

P433

Q34369188-585AEB9F-6169-45C7-B90B-EE21FB2B5F9F

P478

Q34369188-75B6E555-DA8E-48DA-9618-28AFD36D1D3C

P577

Q34369188-8BC76463-711C-484C-8052-452E832DCA9F

P5875

Q34369188-76A46B5A-3E78-4C56-A122-EE6F65FFA862

P698

Q34369188-96C849BA-74B4-4D2A-8580-5887D6F123DD

P356

J.SEMARTHRIT.2013.08.003

P1433

Seminars in Arthritis and Rheumatism

P1476

Comparative cancer risk associ ...... odifying anti-rheumatic drugs.

@en

P2093

Daniel H Solomon

http://www.w3.org/2001/XMLSchema#string

George Reed

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Greenberg

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Curtis

http://www.w3.org/2001/XMLSchema#string

Joel M Kremer

http://www.w3.org/2001/XMLSchema#string

Leslie R Harrold

http://www.w3.org/2001/XMLSchema#string

Marc C Hochberg

http://www.w3.org/2001/XMLSchema#string

Mark Fisher

http://www.w3.org/2001/XMLSchema#string

Peter Tsao

http://www.w3.org/2001/XMLSchema#string

Victoria Furer

http://www.w3.org/2001/XMLSchema#string

P304

489-497

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SEMARTHRIT.2013.08.003

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256467710

http://www.w3.org/2001/XMLSchema#string

P698

24012043

http://www.w3.org/2001/XMLSchema#string